Downregulation of ribonucleotide reductase subunits M2 induces apoptosis and G1 arrest of cervical cancer cells

Wang,Nan; Li,Yong; Zhou,Jianhong

doi:10.3892/ol.2018.7806

Downregulation of ribonucleotide reductase subunits M2 induces apoptosis and G1 arrest of cervical cancer cells

Authors:
- Nan Wang
- Yong Li
- Jianhong Zhou
View Affiliations

Affiliations: Laboratory of Molecular Biology, College of Life Sciences, Jiaying University, Meizhou, Guangdong 514015, P.R. China, Key Laboratory of Molecular Biophysics of The Ministry of Education, College of Life Science and Technology, Center for Human Genome Research, Huazhong University of Science and Technology, Wuhan, Hubei 430074, P.R. China
Published online on: January 16, 2018 https://doi.org/10.3892/ol.2018.7806
Pages: 3719-3725
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ribonucleotide reductase subunit M2 (RRM2) is associated with the biological behaviours of cancers, including apoptosis, cell proliferation, invasion, cell cycle and migration. Previous studies have suggested that the expression of RRM2 plays critical roles in tumorigenesis in several cancer types. However, the precise molecular mechanism remains unknown. We previously identified RRM2 as a novel downstream target that is activated by human papillomavirus E7, which activates the extracellular signal‑regulated kinase 1/2 signalling pathway, but further studies are warranted to establish RRM2 as a therapeutic target. The results of the present study indicate that RRM2 is associated with cervical cancer cell apoptosis and proliferation. The downregulation of RRM2 significantly increased apoptosis, promoted cell cycle arrest at the G1 phase in vitro and inhibited tumour formation in nude mice transplant models in vivo. These results highlight the potential for inhibition of RRM2 expression as a promising therapeutic target for human cervical cancer treatment.

View Figures

View References

1	Bodily JM, Mehta KP and Laimins LA: Human papillomavirus E7 enhances hypoxia-inducible factor 1-mediated transcription by inhibiting binding of histone deacetylases. Cancer Res. 71:1187–1195. 2011. View Article : Google Scholar : PubMed/NCBI
2	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
3	Hildesheim A and Wang SS: Host and viral genetics and risk of cervical cancer: A review. Virus Res. 89:229–240. 2002. View Article : Google Scholar : PubMed/NCBI
4	Mansur CP and Androphy EJ: Cellular transformation by papillomavirus oncoproteins. Biochim Biophys Acta. 1155:323–345. 1993.PubMed/NCBI
5	Wang N, Zhan T, Ke T, Huang X, Ke D, Wang Q and Li H: Increased expression of RRM2 by human papillomavirus E7 oncoprotein promotes angiogenesis in cervical cancer. Br J Cancer. 110:1034–44. 2014. View Article : Google Scholar : PubMed/NCBI
6	Nordlund P and Reichard P: Ribonucleotide reductases. Annu Rev Biochem. 75:681–706. 2006. View Article : Google Scholar : PubMed/NCBI
7	Tanaka H, Arakawa H, Yamaguchi T, Shiraishi K, Fukuda S, Matsui K, Takei Y and Nakamura Y: A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature. 404:42–49. 2000. View Article : Google Scholar : PubMed/NCBI
8	Engström Y, Eriksson S, Jildevik I, Skog S, Thelander L and Tribukait B: Cell cycle-dependent expression of mammalian ribonucleotide reductase. Differential regulation of the two subunits. J Biol Chem. 260:9114–9116. 1985.PubMed/NCBI
9	Zhou BS, Tsai P, Ker R, Tsai J, Ho R, Yu J, Shih J and Yen Y: Overexpression oftransfected human ribonucleotide reductase M2 subunitin human cancer cells enhances their invasive potential. Clin Exp Metastasis. 16:43–49. 1998. View Article : Google Scholar : PubMed/NCBI
10	Zhang K, Hu S, Wu J, Chen L, Lu J, Wang X, Liu X, Zhou B and Yen Y: Overexpression of RRM2 decreases thrombspondin-1 and increases VEGF production in human cancer cells in vitro and in vivo: Implication of RRM2 in angiogenesis. Mol Cancer. 8:11–22. 2009. View Article : Google Scholar : PubMed/NCBI
11	Liu X, Zhang H, Lai L, Wang X, Loera S, Xue L, He H, Zhang K, Hu S, Huang Y, et al: Ribonucleotide reductase small subunit M2 serves as a prognostic biomarker and predicts poor survival of colorectal cancers. Clin Sci (Lond). 124:567–578. 2013. View Article : Google Scholar : PubMed/NCBI
12	Duxbury MS and Whang EE: RRM2 induces NF-kappaB-dependent MMP-9 activation and enhances cellular invasiveness. Biochem Biophys Res Commun. 354:190–196. 2007. View Article : Google Scholar : PubMed/NCBI
13	Fan H, Villegas C, Huang A and Wright JA: The mammalian ribonucleotide reductase R2 component cooperates with a variety of oncogenes in mechanisms of cellular transformation. Cancer Res. 58:1650–1653. 1998.PubMed/NCBI
14	Chabes AL, Björklund S and Thelander L: S Phase-specific transcription of the mouse ribonucleotide reductase R2 gene requires both a proximal repressive E2F-binding site and an upstream promoter activating region. J Biol Chem. 279:10796–10807. 2004. View Article : Google Scholar : PubMed/NCBI
15	Zhang M, Wang J, Yao R and Wang L: Small interfering RNA (siRNA)-mediated silencing of the M2 subunit of ribonucleotide reductase: A novel therapeutic strategy in ovarian cancer. Int J Gynecol Cancer. 23:659–666. 2013. View Article : Google Scholar : PubMed/NCBI
16	Hanahan D and Weinberg RA: The hallmarks of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar : PubMed/NCBI
17	Fulda S and Vucic D: Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Discov. 11:109–124. 2012. View Article : Google Scholar : PubMed/NCBI
18	Vermeulen K, Van Bockstaele DR and Berneman ZN: The cell cycle: A review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif. 36:131–149. 2003. View Article : Google Scholar : PubMed/NCBI
19	Chen HZ, Tsai SY and Leone G: Emerging roles of E2Fs in cancer: An exit from cell cycle control. Nat Rev Cancer. 9:785–797. 2009. View Article : Google Scholar : PubMed/NCBI
20	Su YF, Wu TF, Ko JL, Tsai HT, Tee YT, Chien MH, Chou CH, Lin WL, Low HY, Chou MY, et al: The expression of ribonucleotide reductase M2 in the carcinogenesis of uterine cervix and its relationship with clinicopathological characteristics and prognosis of cancer patients. PLoS One. 9:e 916442014. View Article : Google Scholar
21	Pecorelli S: Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet. 105:103–104. 2009. View Article : Google Scholar : PubMed/NCBI
22	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
23	Wang N, Zhou Y, Zheng L and Li H: miR-31 is an independent prognostic factor and functions as an oncomir in cervical cancer via targeting ARID1A. Gynecol Oncol. 134:129–137. 2014. View Article : Google Scholar : PubMed/NCBI
24	Molina JR and Adjei AA: The Ras/Raf/MAPK pathway. J Thorac Oncol. 1:7–9. 2006. View Article : Google Scholar : PubMed/NCBI
25	Li XD, Zhang YJ and Han JC: Betulin inhibits lung carcinoma proliferation through activation of AMPK signaling. Tumour Bio. l35:1–11158. 2014.
26	Liu X, Zhou B, Xue L, Yen F, Chu P, Un F and Yen Y: Ribonucleotide reductase subunits M2 and p53R2 are potential biomarkers for metastasis of colon cancer. Clin Colorectal Cancer. 6:374–381. 2007. View Article : Google Scholar : PubMed/NCBI
27	Souglakos J, Boukovinas I, Taron M, Mendez P, Mavroudis D, Tripaki M, Hatzidaki D, Koutsopoulos A, Stathopoulos E, Georgoulias V and Rosell R: Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine. Br J Cancer. 98:1710–1715. 2008. View Article : Google Scholar : PubMed/NCBI
28	Kang W, Tong JH, Chan AW, Zhao J, Wang S, Dong Y, Sin FM, Yeung S, Cheng AS, Yu J and To K: Targeting ribonucleotide reductase M2 subunit by small interfering RNA exerts anti-oncogenic effects in gastric adenocarcinoma. Oncol Rep. 31:2579–2586. 2014. View Article : Google Scholar : PubMed/NCBI
29	Ferrandina G, Mey V, Nannizzi S, Ricciardi S, Petrillo M, Ferlini C, Danesi R, Scambia G and Del Tacca M: Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer. Cancer Chemother Pharmacol. 65:679–686. 2010. View Article : Google Scholar : PubMed/NCBI
30	Kretschxmer C, Sterner-Kock A, Siedentopf F, Schoenegg W, Schlag PM and Kemmner W: Identification of early molecular markers for breast cancer. Mol Cancer. 10:152011. View Article : Google Scholar : PubMed/NCBI
31	Morikawa T, Maeda D, Kume H, Homma Y and Fukayama M: Ribonucleotide reductase M2 subunit is a novel diagnostic marker and a potential therapeutic target in bladder cancer. Histopathology. 57:885–892. 2010. View Article : Google Scholar : PubMed/NCBI